Table 4. Change in the study parameters from baseline to three months of metformin therapy in responders and non-responders receiving atorvastatin.
| Parameter | Non-responders receiving atorvastatin (n = 62) | Responders receiving atorvastatin (n = 47) | ||||
|---|---|---|---|---|---|---|
| Baseline | After 3 months | p value | Baseline | After 3 months | p value | |
| Systolic blood pressure (mmHg) | 133.40±15.12 | 127.64±13.75 | 0.001 | 126.60±14.49 | 118.47±20.25 | 0.009 |
| Diastolic blood pressure (mmHg) | 80.98±9.82 | 77.41±10.55 | 0.004 | 78.19±8.50 | 75.64±8.57 | 0.058 |
| BMI (kg/m2) | 31.05±5.48 | 30.68±5.44 | 0.003 | 31.97±5.36 | 31.36±5.53 | <0.001 |
| Fasting glucose (mmol/L) | 7.73±1.36 | 7.69±2.22 | 0.862 | 7.89±1.53 | 6.63±1.15 | <0.001 |
| HbA1c (%) | 7.45±0.72 | 7.61±1.13 | 0.14 | 7.91±0.78 | 6.31±0.69 | <0.001 |
| ALT (μkat/L) | 0.43±0.15 | 0.43±0.20 | 0.944 | 0.42±0.18 | 0.37±0.12 | 0.052 |
| AST (μkat/L) | 0.44±0.19 | 0.43±0.22 | 0.78 | 0.40±0.16 | 0.38±0.13 | 0.401 |
| TG (mmol/L) | 2.04±0.92 | 1.91±0.77 | 0.087 | 2.11±0.82 | 1.73±0.63 | 0.006 |
| TC (mmol/L) | 4.91±1.18 | 4.62±0.89 | 0.11 | 5.03±0.97 | 4.32±0.74 | <0.001 |
| HDL- C (mmol/L) | 1.30±0.42 | 1.25±0.34 | 0.445 | 1.09±0.27 | 1.26±0.35 | 0.002 |
| LDL- C (mmol/L) | 2.71±0.93 | 2.40±0.75 | 0.037 | 2.95±0.91 | 2.22±0.69 | <0.001 |
| LDL-C/HDL-C | 2.28±0.90 | 2.03±0.76 | 0.049 | 2.95±1.41 | 1.91±0.82 | <0.001 |
| TC/HDL-C | 4.02±1.10 | 3.85±1.06 | 0.237 | 4.98±1.93 | 3.63±1.05 | <0.001 |
| AIP a | 0.54±0.22 | 0.52±0.23 | 0.353 | 0.63±0.25 | 0.48±0.21 | <0.001 |
Data are means ± SD
a Atherogenic index of plasma (the logarithmic transformation of TG/HDL-C)